Robert Griffin
Concepts (687)
Concept scores are derived automatically based on a person's publications. Keywords in the their attributed publications are matched to keywords from the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). The strength of a person's concept scores is based not only on the number of corresponding publications, but also how relevant the concepts are to the overall topics of the publications, how long ago the publications were written, whether the person was the first or senior author, and how many other people have written about the topic.Concepts cannot be directly edited. You can help ensure your concepts are accurate by making sure your attributed publications are correct and up-to-date. We recommend checking over your attributed publications list every three to four months.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Neoplasms | 34 | 2023 | 1315 | 4.410 |
Why?
| Hyperthermia, Induced | 17 | 2019 | 107 | 3.900 |
Why?
| Mammary Neoplasms, Experimental | 12 | 2015 | 135 | 3.470 |
Why?
| Radiotherapy | 10 | 2021 | 138 | 3.160 |
Why?
| Gold | 9 | 2023 | 164 | 2.720 |
Why?
| Radiation-Sensitizing Agents | 11 | 2023 | 55 | 2.200 |
Why?
| Air Pollutants | 12 | 2023 | 70 | 2.190 |
Why?
| Mice | 74 | 2024 | 6413 | 2.090 |
Why?
| Nanostructures | 5 | 2023 | 53 | 1.960 |
Why?
| Animals | 97 | 2024 | 14385 | 1.910 |
Why?
| Exosomes | 7 | 2022 | 45 | 1.800 |
Why?
| Cell Line, Tumor | 38 | 2024 | 1550 | 1.770 |
Why?
| Phototherapy | 5 | 2022 | 53 | 1.670 |
Why?
| Angiogenesis Inhibitors | 8 | 2017 | 203 | 1.660 |
Why?
| Radiation Tolerance | 9 | 2020 | 86 | 1.640 |
Why?
| Blood Vessels | 9 | 2020 | 78 | 1.580 |
Why?
| Metal Nanoparticles | 4 | 2023 | 96 | 1.570 |
Why?
| Nanoparticles | 6 | 2022 | 173 | 1.530 |
Why?
| Neoplasms, Experimental | 6 | 2020 | 115 | 1.520 |
Why?
| Galectin 1 | 4 | 2017 | 21 | 1.500 |
Why?
| Aerosols | 10 | 2023 | 76 | 1.470 |
Why?
| Oxygen | 12 | 2020 | 361 | 1.400 |
Why?
| Polyethylene Glycols | 4 | 2022 | 106 | 1.380 |
Why?
| Bystander Effect | 4 | 2020 | 22 | 1.290 |
Why?
| Carcinoma, Squamous Cell | 6 | 2019 | 384 | 1.270 |
Why?
| Lung Neoplasms | 8 | 2024 | 642 | 1.270 |
Why?
| Combined Modality Therapy | 17 | 2022 | 692 | 1.190 |
Why?
| Endothelial Cells | 7 | 2021 | 294 | 1.160 |
Why?
| Tumor Necrosis Factor-alpha | 8 | 2019 | 434 | 1.090 |
Why?
| Sulfates | 2 | 2023 | 27 | 1.090 |
Why?
| Fibrosarcoma | 7 | 2019 | 13 | 1.080 |
Why?
| Neovascularization, Pathologic | 9 | 2021 | 168 | 1.060 |
Why?
| Liposomes | 2 | 2022 | 53 | 0.980 |
Why?
| Humans | 99 | 2024 | 54246 | 0.960 |
Why?
| Oxygen Consumption | 4 | 2020 | 223 | 0.960 |
Why?
| Ozone | 6 | 2022 | 19 | 0.950 |
Why?
| Peptides | 10 | 2022 | 276 | 0.930 |
Why?
| Cell Communication | 3 | 2021 | 72 | 0.920 |
Why?
| Antineoplastic Agents | 12 | 2024 | 1300 | 0.920 |
Why?
| Fluorescent Dyes | 5 | 2022 | 116 | 0.910 |
Why?
| Mice, Inbred BALB C | 8 | 2020 | 368 | 0.900 |
Why?
| Proteins | 6 | 2010 | 376 | 0.880 |
Why?
| Indocyanine Green | 2 | 2013 | 39 | 0.860 |
Why?
| Apoptosis | 9 | 2023 | 1300 | 0.840 |
Why?
| Neoplastic Cells, Circulating | 3 | 2017 | 93 | 0.810 |
Why?
| Radiotherapy, Intensity-Modulated | 4 | 2022 | 170 | 0.750 |
Why?
| Flow Cytometry | 5 | 2017 | 546 | 0.750 |
Why?
| Radiosurgery | 6 | 2020 | 122 | 0.750 |
Why?
| Carcinoma, Non-Small-Cell Lung | 4 | 2024 | 164 | 0.720 |
Why?
| Thiadiazoles | 2 | 2019 | 15 | 0.710 |
Why?
| Antioxidants | 2 | 2020 | 297 | 0.710 |
Why?
| Radiation Dosage | 2 | 2020 | 170 | 0.710 |
Why?
| Radiotherapy Dosage | 6 | 2022 | 243 | 0.700 |
Why?
| Immunotherapy | 2 | 2021 | 263 | 0.700 |
Why?
| Pyrimidines | 7 | 2021 | 196 | 0.690 |
Why?
| Benzeneacetamides | 1 | 2019 | 9 | 0.690 |
Why?
| Glutaminase | 1 | 2019 | 14 | 0.690 |
Why?
| Models, Theoretical | 7 | 2015 | 184 | 0.680 |
Why?
| Radiation-Protective Agents | 1 | 2020 | 116 | 0.670 |
Why?
| Head and Neck Neoplasms | 3 | 2019 | 335 | 0.660 |
Why?
| Epigenesis, Genetic | 2 | 2019 | 399 | 0.660 |
Why?
| Cell Survival | 14 | 2019 | 657 | 0.650 |
Why?
| Drug Delivery Systems | 2 | 2022 | 151 | 0.650 |
Why?
| Arsenicals | 3 | 2007 | 14 | 0.640 |
Why?
| Oxides | 3 | 2007 | 19 | 0.640 |
Why?
| Information Dissemination | 2 | 2016 | 104 | 0.640 |
Why?
| Uncertainty | 2 | 2022 | 46 | 0.630 |
Why?
| Molecular Imaging | 2 | 2015 | 60 | 0.630 |
Why?
| Xenograft Model Antitumor Assays | 13 | 2021 | 219 | 0.610 |
Why?
| Gamma Rays | 2 | 2020 | 56 | 0.600 |
Why?
| Bone and Bones | 2 | 2012 | 516 | 0.600 |
Why?
| Radiotherapy, Conformal | 2 | 2019 | 54 | 0.600 |
Why?
| Oxidation-Reduction | 5 | 2023 | 382 | 0.590 |
Why?
| Science | 1 | 2016 | 17 | 0.590 |
Why?
| Molecular Targeted Therapy | 3 | 2018 | 128 | 0.590 |
Why?
| Female | 35 | 2021 | 28418 | 0.580 |
Why?
| Pneumonia, Viral | 1 | 2020 | 184 | 0.580 |
Why?
| Disease Models, Animal | 11 | 2020 | 1639 | 0.580 |
Why?
| Mice, Nude | 12 | 2019 | 283 | 0.580 |
Why?
| Cell Proliferation | 11 | 2021 | 1096 | 0.570 |
Why?
| Coronavirus Infections | 1 | 2020 | 192 | 0.570 |
Why?
| Mouth Neoplasms | 4 | 2015 | 25 | 0.550 |
Why?
| Cell Hypoxia | 6 | 2015 | 87 | 0.520 |
Why?
| Radiobiology | 4 | 2020 | 19 | 0.510 |
Why?
| Pandemics | 1 | 2020 | 579 | 0.510 |
Why?
| Environmental Monitoring | 7 | 2023 | 71 | 0.500 |
Why?
| Carcinoma | 2 | 2013 | 153 | 0.490 |
Why?
| Laser Therapy | 2 | 2013 | 91 | 0.490 |
Why?
| Radiotherapy Planning, Computer-Assisted | 5 | 2022 | 243 | 0.490 |
Why?
| Sanitation | 1 | 2014 | 20 | 0.490 |
Why?
| Solanum tuberosum | 1 | 2014 | 11 | 0.490 |
Why?
| Enzyme Inhibitors | 6 | 2018 | 446 | 0.480 |
Why?
| Bone Marrow Neoplasms | 1 | 2013 | 15 | 0.480 |
Why?
| Coloring Agents | 2 | 2013 | 84 | 0.470 |
Why?
| Chemokines | 1 | 2013 | 96 | 0.470 |
Why?
| Tumor Microenvironment | 7 | 2022 | 209 | 0.460 |
Why?
| Spectrum Analysis, Raman | 3 | 2019 | 68 | 0.460 |
Why?
| Gene Expression Regulation, Neoplastic | 3 | 2018 | 866 | 0.460 |
Why?
| Infrared Rays | 2 | 2019 | 27 | 0.450 |
Why?
| Tumor Cells, Cultured | 8 | 2019 | 477 | 0.450 |
Why?
| Signal Transduction | 8 | 2021 | 1753 | 0.430 |
Why?
| Adult Stem Cells | 1 | 2012 | 10 | 0.430 |
Why?
| Cell Death | 7 | 2019 | 223 | 0.420 |
Why?
| Conservation of Natural Resources | 3 | 2017 | 37 | 0.420 |
Why?
| Lignin | 1 | 2011 | 3 | 0.420 |
Why?
| Environmental Pollution | 1 | 2011 | 11 | 0.410 |
Why?
| Bone Neoplasms | 2 | 2011 | 193 | 0.410 |
Why?
| DNA Damage | 5 | 2019 | 357 | 0.410 |
Why?
| Mice, Inbred C3H | 9 | 2015 | 82 | 0.400 |
Why?
| Ecosystem | 3 | 2017 | 91 | 0.400 |
Why?
| Antibodies, Monoclonal | 3 | 2020 | 562 | 0.400 |
Why?
| Dose-Response Relationship, Radiation | 10 | 2020 | 204 | 0.390 |
Why?
| Photochemical Processes | 1 | 2010 | 10 | 0.390 |
Why?
| Time Factors | 12 | 2017 | 3212 | 0.390 |
Why?
| Photons | 2 | 2020 | 18 | 0.390 |
Why?
| Saliva | 3 | 2007 | 63 | 0.390 |
Why?
| Air Pollution | 2 | 2022 | 45 | 0.380 |
Why?
| Models, Biological | 6 | 2018 | 823 | 0.380 |
Why?
| Protein Kinase Inhibitors | 4 | 2023 | 216 | 0.370 |
Why?
| Cytokines | 1 | 2013 | 676 | 0.370 |
Why?
| Phenols | 1 | 2011 | 120 | 0.370 |
Why?
| Melanoma, Experimental | 2 | 2021 | 49 | 0.360 |
Why?
| Methionine | 3 | 2020 | 146 | 0.360 |
Why?
| Breast Neoplasms | 6 | 2017 | 1248 | 0.360 |
Why?
| Cell Line | 6 | 2021 | 1153 | 0.360 |
Why?
| Aniline Compounds | 3 | 2021 | 48 | 0.350 |
Why?
| Rats | 11 | 2022 | 3415 | 0.350 |
Why?
| Volatile Organic Compounds | 2 | 2022 | 5 | 0.350 |
Why?
| Particulate Matter | 4 | 2023 | 56 | 0.340 |
Why?
| Hydroxyl Radical | 2 | 2010 | 10 | 0.340 |
Why?
| Atmosphere | 4 | 2019 | 10 | 0.340 |
Why?
| Receptor, erbB-2 | 5 | 2016 | 79 | 0.340 |
Why?
| Radiation Injuries | 3 | 2020 | 153 | 0.340 |
Why?
| Indoles | 2 | 2021 | 289 | 0.330 |
Why?
| Radiation | 2 | 2020 | 17 | 0.330 |
Why?
| Weightlessness Simulation | 2 | 2020 | 23 | 0.330 |
Why?
| Drug Carriers | 2 | 2013 | 81 | 0.320 |
Why?
| Precancerous Conditions | 2 | 2010 | 93 | 0.320 |
Why?
| Cell Membrane Permeability | 1 | 2008 | 28 | 0.320 |
Why?
| Caspase Inhibitors | 1 | 2008 | 31 | 0.320 |
Why?
| China | 3 | 2023 | 104 | 0.310 |
Why?
| Clinical Laboratory Techniques | 1 | 2008 | 31 | 0.310 |
Why?
| Forecasting | 4 | 2020 | 161 | 0.310 |
Why?
| Freezing | 2 | 2004 | 15 | 0.310 |
Why?
| Caspases | 1 | 2007 | 146 | 0.300 |
Why?
| Adenocarcinoma | 1 | 2011 | 428 | 0.300 |
Why?
| Vascular Neoplasms | 1 | 2007 | 20 | 0.300 |
Why?
| Nanotubes, Carbon | 2 | 2017 | 70 | 0.290 |
Why?
| Radiotherapy, Image-Guided | 2 | 2016 | 25 | 0.290 |
Why?
| Texas | 6 | 2022 | 160 | 0.280 |
Why?
| Glutamine | 2 | 2019 | 168 | 0.280 |
Why?
| Glutathione | 2 | 2019 | 330 | 0.280 |
Why?
| Cryotherapy | 2 | 2011 | 16 | 0.270 |
Why?
| Microscopy, Fluorescence | 3 | 2018 | 198 | 0.270 |
Why?
| Melanoma | 2 | 2020 | 313 | 0.270 |
Why?
| Organs at Risk | 3 | 2022 | 70 | 0.270 |
Why?
| History, 20th Century | 2 | 2020 | 114 | 0.270 |
Why?
| Male | 18 | 2021 | 27312 | 0.270 |
Why?
| Hindlimb | 2 | 2004 | 25 | 0.260 |
Why?
| Hydrogen-Ion Concentration | 5 | 2005 | 194 | 0.260 |
Why?
| Ovarian Neoplasms | 2 | 2008 | 472 | 0.250 |
Why?
| Cell Culture Techniques | 2 | 2019 | 112 | 0.250 |
Why?
| Oxidants, Photochemical | 1 | 2004 | 3 | 0.250 |
Why?
| Smog | 1 | 2004 | 6 | 0.240 |
Why?
| Disease Progression | 4 | 2019 | 913 | 0.240 |
Why?
| Porphyrins | 1 | 2023 | 12 | 0.240 |
Why?
| Nitroimidazoles | 2 | 2015 | 17 | 0.240 |
Why?
| Oxidants | 1 | 2004 | 64 | 0.240 |
Why?
| Vascular Endothelial Growth Factor A | 5 | 2017 | 230 | 0.230 |
Why?
| Proteomics | 4 | 2021 | 343 | 0.230 |
Why?
| Radiometry | 2 | 2016 | 124 | 0.230 |
Why?
| Photochemotherapy | 1 | 2023 | 37 | 0.230 |
Why?
| Sulfur Oxides | 1 | 2023 | 1 | 0.230 |
Why?
| Gulf of Mexico | 1 | 2023 | 5 | 0.230 |
Why?
| Receptor Protein-Tyrosine Kinases | 2 | 2008 | 52 | 0.230 |
Why?
| Proteasome Endopeptidase Complex | 2 | 2021 | 131 | 0.230 |
Why?
| Partial Pressure | 3 | 2011 | 17 | 0.230 |
Why?
| Carcinoma, Hepatocellular | 2 | 2023 | 203 | 0.230 |
Why?
| Halogens | 1 | 2022 | 4 | 0.220 |
Why?
| Organic Anion Transporters | 1 | 2022 | 2 | 0.220 |
Why?
| Phosphatidylethanolamines | 1 | 2022 | 13 | 0.220 |
Why?
| Lipid Bilayers | 1 | 2022 | 12 | 0.220 |
Why?
| Environmental Exposure | 2 | 2022 | 205 | 0.220 |
Why?
| Tumor Burden | 3 | 2010 | 142 | 0.220 |
Why?
| Bile | 1 | 2022 | 24 | 0.220 |
Why?
| Chloral Hydrate | 1 | 2022 | 20 | 0.220 |
Why?
| Receptors, Growth Factor | 1 | 2002 | 6 | 0.220 |
Why?
| Receptors, Fibroblast Growth Factor | 1 | 2002 | 8 | 0.220 |
Why?
| Tissue Distribution | 1 | 2022 | 178 | 0.220 |
Why?
| Receptors, Platelet-Derived Growth Factor | 1 | 2002 | 5 | 0.220 |
Why?
| X-Rays | 3 | 2016 | 57 | 0.210 |
Why?
| NAD(P)H Dehydrogenase (Quinone) | 3 | 2007 | 24 | 0.210 |
Why?
| Naphthoquinones | 3 | 2007 | 14 | 0.210 |
Why?
| Biological Transport | 2 | 2021 | 195 | 0.210 |
Why?
| Cholesterol | 1 | 2022 | 155 | 0.210 |
Why?
| Protons | 1 | 2022 | 81 | 0.210 |
Why?
| Protein Binding | 5 | 2020 | 736 | 0.210 |
Why?
| Plasmodium falciparum | 1 | 2021 | 18 | 0.210 |
Why?
| Boron Compounds | 1 | 2021 | 18 | 0.210 |
Why?
| Malaria, Falciparum | 1 | 2021 | 12 | 0.210 |
Why?
| Floods | 1 | 2021 | 3 | 0.210 |
Why?
| Liver Neoplasms | 2 | 2023 | 352 | 0.200 |
Why?
| Pyrroles | 1 | 2002 | 78 | 0.200 |
Why?
| Nucleotides, Cyclic | 1 | 2021 | 4 | 0.200 |
Why?
| Spheroids, Cellular | 3 | 2019 | 26 | 0.200 |
Why?
| High-Intensity Focused Ultrasound Ablation | 2 | 2011 | 15 | 0.200 |
Why?
| Endosomes | 1 | 2021 | 37 | 0.200 |
Why?
| Optical Imaging | 2 | 2020 | 30 | 0.200 |
Why?
| Neoplasm Proteins | 3 | 2017 | 359 | 0.200 |
Why?
| Proto-Oncogene Proteins c-met | 1 | 2021 | 21 | 0.200 |
Why?
| Exons | 1 | 2021 | 105 | 0.190 |
Why?
| Chronic Pain | 1 | 2023 | 147 | 0.190 |
Why?
| Radiation, Ionizing | 4 | 2018 | 120 | 0.190 |
Why?
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2018 | 60 | 0.190 |
Why?
| Proteasome Inhibitors | 1 | 2021 | 110 | 0.190 |
Why?
| Proton Therapy | 1 | 2020 | 9 | 0.190 |
Why?
| Spectrum Analysis | 1 | 2020 | 79 | 0.190 |
Why?
| Thymus Gland | 1 | 2020 | 45 | 0.190 |
Why?
| Cells, Cultured | 4 | 2020 | 1737 | 0.190 |
Why?
| History, 21st Century | 1 | 2020 | 62 | 0.190 |
Why?
| Clinical Trials as Topic | 2 | 2020 | 490 | 0.190 |
Why?
| Cell Transformation, Neoplastic | 3 | 2018 | 200 | 0.190 |
Why?
| Neural Stem Cells | 1 | 2020 | 27 | 0.190 |
Why?
| Heavy Ion Radiotherapy | 1 | 2019 | 1 | 0.180 |
Why?
| Adenosine Triphosphate | 1 | 2021 | 242 | 0.180 |
Why?
| Cell Differentiation | 2 | 2020 | 720 | 0.180 |
Why?
| Receptor, TIE-2 | 2 | 2017 | 18 | 0.180 |
Why?
| Carcinoma, Lewis Lung | 1 | 2019 | 11 | 0.180 |
Why?
| Calixarenes | 2 | 2017 | 9 | 0.180 |
Why?
| Radiation Oncology | 1 | 2019 | 18 | 0.180 |
Why?
| Cone-Beam Computed Tomography | 2 | 2016 | 34 | 0.180 |
Why?
| Autoantibodies | 1 | 2020 | 132 | 0.180 |
Why?
| Spleen | 1 | 2020 | 186 | 0.180 |
Why?
| Societies, Medical | 1 | 2020 | 194 | 0.180 |
Why?
| Intracellular Signaling Peptides and Proteins | 1 | 2020 | 151 | 0.180 |
Why?
| Interleukin-6 | 2 | 2020 | 315 | 0.170 |
Why?
| Whole-Body Irradiation | 1 | 2020 | 160 | 0.170 |
Why?
| Preservation, Biological | 1 | 2018 | 10 | 0.170 |
Why?
| Lymphocytes, Tumor-Infiltrating | 1 | 2019 | 74 | 0.170 |
Why?
| Drug Evaluation, Preclinical | 3 | 2015 | 158 | 0.170 |
Why?
| Astrocytes | 1 | 2020 | 142 | 0.170 |
Why?
| Ephrin-B2 | 1 | 2018 | 6 | 0.170 |
Why?
| Environmental Pollutants | 1 | 2020 | 101 | 0.170 |
Why?
| CD8-Positive T-Lymphocytes | 1 | 2019 | 116 | 0.170 |
Why?
| Lipopolysaccharides | 1 | 2019 | 199 | 0.170 |
Why?
| Paracrine Communication | 1 | 2018 | 12 | 0.170 |
Why?
| Methionine Adenosyltransferase | 1 | 2018 | 20 | 0.170 |
Why?
| Cystic Fibrosis | 1 | 2021 | 157 | 0.170 |
Why?
| Microinjections | 1 | 2018 | 32 | 0.170 |
Why?
| Myocytes, Cardiac | 1 | 2019 | 137 | 0.160 |
Why?
| Membrane Proteins | 1 | 2021 | 389 | 0.160 |
Why?
| Calibration | 1 | 2018 | 59 | 0.160 |
Why?
| Biological Assay | 1 | 2018 | 55 | 0.160 |
Why?
| Galectins | 1 | 2018 | 5 | 0.160 |
Why?
| Ubiquitin-Activating Enzymes | 1 | 2018 | 4 | 0.160 |
Why?
| Nucleosides | 1 | 2018 | 5 | 0.160 |
Why?
| Indazoles | 1 | 2018 | 55 | 0.160 |
Why?
| Erythrocyte Membrane | 1 | 2017 | 15 | 0.160 |
Why?
| California | 4 | 2010 | 90 | 0.160 |
Why?
| Prostatic Neoplasms | 2 | 2013 | 415 | 0.160 |
Why?
| Intercellular Signaling Peptides and Proteins | 1 | 2018 | 122 | 0.160 |
Why?
| Oceans and Seas | 1 | 2017 | 24 | 0.160 |
Why?
| Treatment Outcome | 5 | 2020 | 5604 | 0.160 |
Why?
| Gastrointestinal Tract | 1 | 2019 | 135 | 0.150 |
Why?
| Structure-Activity Relationship | 7 | 2021 | 423 | 0.150 |
Why?
| Histocompatibility Antigens Class II | 1 | 2017 | 43 | 0.150 |
Why?
| Small Molecule Libraries | 1 | 2018 | 72 | 0.150 |
Why?
| Scavenger Receptors, Class E | 1 | 2019 | 217 | 0.150 |
Why?
| MicroRNAs | 1 | 2021 | 386 | 0.150 |
Why?
| Epitope Mapping | 1 | 2017 | 12 | 0.150 |
Why?
| Vehicle Emissions | 1 | 2017 | 17 | 0.150 |
Why?
| Receptors, Interleukin-6 | 1 | 2017 | 29 | 0.150 |
Why?
| Models, Molecular | 4 | 2021 | 423 | 0.150 |
Why?
| Pyridazines | 2 | 2008 | 12 | 0.150 |
Why?
| Ammonia | 1 | 2017 | 73 | 0.150 |
Why?
| Silver | 1 | 2017 | 54 | 0.150 |
Why?
| Biomass | 1 | 2016 | 22 | 0.150 |
Why?
| Myocardial Infarction | 1 | 2021 | 424 | 0.150 |
Why?
| Random Allocation | 2 | 2015 | 312 | 0.150 |
Why?
| Sulfonamides | 1 | 2018 | 146 | 0.140 |
Why?
| Bacteria | 1 | 2018 | 258 | 0.140 |
Why?
| Dendritic Cells | 1 | 2017 | 142 | 0.140 |
Why?
| Mice, Inbred Strains | 3 | 2013 | 198 | 0.140 |
Why?
| Epithelial Cells | 1 | 2018 | 255 | 0.140 |
Why?
| Antineoplastic Combined Chemotherapy Protocols | 2 | 2016 | 1056 | 0.140 |
Why?
| Antibodies | 1 | 2017 | 178 | 0.140 |
Why?
| Extraterrestrial Environment | 1 | 2016 | 8 | 0.140 |
Why?
| Radiation Protection | 1 | 2016 | 55 | 0.140 |
Why?
| Chemistry, Organic | 2 | 2019 | 2 | 0.140 |
Why?
| Neoplasm Transplantation | 2 | 2007 | 94 | 0.140 |
Why?
| Cyclonic Storms | 1 | 2015 | 10 | 0.140 |
Why?
| Extracellular Fluid | 1 | 2015 | 19 | 0.140 |
Why?
| Tomography, Spiral Computed | 1 | 2016 | 56 | 0.130 |
Why?
| Organ Specificity | 1 | 2016 | 126 | 0.130 |
Why?
| Microbubbles | 1 | 2015 | 34 | 0.130 |
Why?
| Organ Sparing Treatments | 1 | 2016 | 54 | 0.130 |
Why?
| Sulfuric Acids | 1 | 2015 | 8 | 0.130 |
Why?
| Carcinoma, Ductal, Breast | 1 | 2016 | 96 | 0.130 |
Why?
| Stromal Cells | 1 | 2015 | 79 | 0.130 |
Why?
| Multiple Myeloma | 1 | 2010 | 3035 | 0.130 |
Why?
| Pressure | 1 | 2015 | 120 | 0.130 |
Why?
| Cell Count | 1 | 2015 | 181 | 0.130 |
Why?
| Biomedical Research | 1 | 2018 | 240 | 0.130 |
Why?
| Tandem Mass Spectrometry | 3 | 2017 | 248 | 0.130 |
Why?
| Necrosis | 3 | 2013 | 208 | 0.130 |
Why?
| Rabbits | 3 | 2010 | 425 | 0.130 |
Why?
| Risk Assessment | 2 | 2017 | 1361 | 0.120 |
Why?
| Imaging, Three-Dimensional | 1 | 2015 | 171 | 0.120 |
Why?
| Carbon Dioxide | 2 | 2005 | 102 | 0.120 |
Why?
| Image Processing, Computer-Assisted | 1 | 2016 | 256 | 0.120 |
Why?
| Mexico | 1 | 2014 | 46 | 0.120 |
Why?
| Hot Temperature | 3 | 2013 | 199 | 0.120 |
Why?
| Brain | 2 | 2020 | 1387 | 0.120 |
Why?
| Contrast Media | 1 | 2015 | 221 | 0.120 |
Why?
| Animals, Inbred Strains | 1 | 2013 | 5 | 0.120 |
Why?
| Reactive Oxygen Species | 2 | 2013 | 491 | 0.120 |
Why?
| Cisplatin | 2 | 2024 | 352 | 0.120 |
Why?
| Polymorphism, Single Nucleotide | 1 | 2017 | 552 | 0.120 |
Why?
| Nanoconjugates | 1 | 2013 | 2 | 0.120 |
Why?
| DNA Methylation | 1 | 2018 | 574 | 0.120 |
Why?
| Food, Genetically Modified | 1 | 2013 | 1 | 0.120 |
Why?
| Food Labeling | 1 | 2013 | 6 | 0.110 |
Why?
| Societies, Scientific | 1 | 2013 | 15 | 0.110 |
Why?
| Antigen-Presenting Cells | 1 | 2013 | 25 | 0.110 |
Why?
| Programmed Cell Death 1 Ligand 2 Protein | 1 | 2013 | 6 | 0.110 |
Why?
| Stress, Psychological | 1 | 2015 | 269 | 0.110 |
Why?
| Ultrasonography | 1 | 2015 | 480 | 0.110 |
Why?
| Nanospheres | 1 | 2013 | 11 | 0.110 |
Why?
| Real-Time Polymerase Chain Reaction | 1 | 2013 | 206 | 0.110 |
Why?
| Nanotechnology | 1 | 2013 | 39 | 0.110 |
Why?
| Programmed Cell Death 1 Receptor | 1 | 2013 | 40 | 0.110 |
Why?
| Nutrition Policy | 1 | 2013 | 51 | 0.110 |
Why?
| Film Dosimetry | 1 | 2012 | 15 | 0.110 |
Why?
| Linear Models | 1 | 2013 | 309 | 0.110 |
Why?
| Mice, Inbred C57BL | 4 | 2020 | 1999 | 0.110 |
Why?
| Gene Expression Profiling | 2 | 2017 | 1138 | 0.110 |
Why?
| Surface Plasmon Resonance | 3 | 2017 | 25 | 0.110 |
Why?
| Blotting, Western | 1 | 2013 | 683 | 0.110 |
Why?
| Reverse Transcriptase Polymerase Chain Reaction | 1 | 2013 | 673 | 0.110 |
Why?
| Glucose | 2 | 2011 | 366 | 0.100 |
Why?
| Oligonucleotide Array Sequence Analysis | 1 | 2013 | 474 | 0.100 |
Why?
| North Carolina | 2 | 2022 | 52 | 0.100 |
Why?
| Gold Colloid | 2 | 2011 | 2 | 0.100 |
Why?
| Acids | 1 | 2011 | 11 | 0.100 |
Why?
| Isomerism | 1 | 2011 | 24 | 0.100 |
Why?
| RNA, Messenger | 2 | 2013 | 1202 | 0.100 |
Why?
| Copper | 1 | 2011 | 48 | 0.100 |
Why?
| Injections, Intravenous | 1 | 2011 | 148 | 0.100 |
Why?
| Aldehydes | 1 | 2011 | 97 | 0.100 |
Why?
| Acenaphthenes | 1 | 2010 | 1 | 0.100 |
Why?
| Nitrogen Oxides | 1 | 2010 | 3 | 0.100 |
Why?
| Gene Expression Regulation | 3 | 2021 | 1062 | 0.100 |
Why?
| Immunohistochemistry | 2 | 2020 | 1089 | 0.100 |
Why?
| Myosins | 1 | 2010 | 19 | 0.100 |
Why?
| Particle Size | 1 | 2010 | 88 | 0.090 |
Why?
| Positron-Emission Tomography | 1 | 2012 | 322 | 0.090 |
Why?
| T-Lymphocytes | 1 | 2013 | 373 | 0.090 |
Why?
| United States | 3 | 2019 | 5200 | 0.090 |
Why?
| Bone Transplantation | 1 | 2010 | 55 | 0.090 |
Why?
| Isoxazoles | 1 | 2009 | 16 | 0.090 |
Why?
| Nitrous Acid | 1 | 2009 | 1 | 0.090 |
Why?
| Free Radicals | 1 | 2009 | 31 | 0.090 |
Why?
| Formaldehyde | 1 | 2009 | 49 | 0.090 |
Why?
| Actins | 1 | 2010 | 132 | 0.090 |
Why?
| Abdomen | 1 | 2010 | 83 | 0.090 |
Why?
| Acetylcysteine | 1 | 2010 | 118 | 0.090 |
Why?
| Protein Transport | 1 | 2010 | 195 | 0.090 |
Why?
| Receptors, G-Protein-Coupled | 1 | 2009 | 55 | 0.090 |
Why?
| Microcirculation | 1 | 2010 | 89 | 0.090 |
Why?
| Naphthalenes | 1 | 2010 | 126 | 0.090 |
Why?
| Glycolysis | 2 | 2021 | 73 | 0.090 |
Why?
| Chemotherapy, Adjuvant | 2 | 2016 | 119 | 0.090 |
Why?
| Coculture Techniques | 2 | 2020 | 160 | 0.090 |
Why?
| Antimetabolites, Antineoplastic | 1 | 2009 | 39 | 0.090 |
Why?
| Administration, Oral | 3 | 2021 | 459 | 0.080 |
Why?
| Glycogen Synthase Kinase 3 | 2 | 2008 | 21 | 0.080 |
Why?
| Cyclin-Dependent Kinase 4 | 1 | 2008 | 15 | 0.080 |
Why?
| Growth Inhibitors | 2 | 2009 | 32 | 0.080 |
Why?
| Methotrexate | 1 | 2009 | 73 | 0.080 |
Why?
| Evoked Potentials, Auditory, Brain Stem | 1 | 2008 | 26 | 0.080 |
Why?
| Nerve Tissue Proteins | 2 | 2020 | 199 | 0.080 |
Why?
| STAT3 Transcription Factor | 2 | 2020 | 87 | 0.080 |
Why?
| Insulin-Like Growth Factor I | 1 | 2009 | 137 | 0.080 |
Why?
| Alkynes | 1 | 2008 | 5 | 0.080 |
Why?
| Up-Regulation | 2 | 2007 | 508 | 0.080 |
Why?
| Cytotoxins | 1 | 2008 | 17 | 0.080 |
Why?
| Regional Blood Flow | 2 | 2005 | 121 | 0.080 |
Why?
| Cryosurgery | 2 | 2011 | 38 | 0.080 |
Why?
| HEK293 Cells | 2 | 2020 | 245 | 0.080 |
Why?
| Chemical Fractionation | 1 | 2007 | 18 | 0.080 |
Why?
| Drinking | 2 | 2020 | 78 | 0.080 |
Why?
| Drug Synergism | 2 | 2005 | 171 | 0.080 |
Why?
| Toxicity Tests | 1 | 2008 | 52 | 0.080 |
Why?
| Fluorescence | 2 | 2018 | 53 | 0.080 |
Why?
| Pyrrolidines | 1 | 2008 | 88 | 0.080 |
Why?
| Cost-Benefit Analysis | 2 | 2021 | 291 | 0.080 |
Why?
| In Situ Nick-End Labeling | 2 | 2004 | 64 | 0.080 |
Why?
| Enzyme Activation | 2 | 2005 | 329 | 0.080 |
Why?
| Computer Simulation | 3 | 2016 | 332 | 0.080 |
Why?
| Sulfides | 2 | 2018 | 32 | 0.070 |
Why?
| Sesquiterpenes | 1 | 2008 | 91 | 0.070 |
Why?
| Hearing Loss, Sensorineural | 1 | 2008 | 82 | 0.070 |
Why?
| Skin | 2 | 2009 | 469 | 0.070 |
Why?
| Angiopoietin-2 | 2 | 2017 | 16 | 0.070 |
Why?
| Angiopoietin-1 | 2 | 2017 | 18 | 0.070 |
Why?
| Concept Formation | 1 | 2006 | 11 | 0.070 |
Why?
| Fibroblast Growth Factor 2 | 2 | 2017 | 33 | 0.070 |
Why?
| Histones | 2 | 2020 | 335 | 0.070 |
Why?
| Interleukin-2 | 1 | 2006 | 75 | 0.070 |
Why?
| Oxidative Stress | 1 | 2012 | 958 | 0.070 |
Why?
| Neurons | 2 | 2020 | 486 | 0.070 |
Why?
| Interleukin-8 | 1 | 2006 | 97 | 0.070 |
Why?
| Matrix Metalloproteinase 9 | 2 | 2017 | 93 | 0.070 |
Why?
| Lasers | 2 | 2019 | 141 | 0.070 |
Why?
| Feasibility Studies | 2 | 2022 | 398 | 0.070 |
Why?
| Mice, SCID | 2 | 2021 | 196 | 0.070 |
Why?
| Mice, Inbred A | 2 | 2003 | 12 | 0.070 |
Why?
| Temperature | 3 | 2018 | 177 | 0.070 |
Why?
| Sarcoma | 1 | 2007 | 73 | 0.070 |
Why?
| Electrophoresis | 1 | 2005 | 18 | 0.070 |
Why?
| Colorectal Neoplasms | 2 | 2006 | 235 | 0.070 |
Why?
| Neoadjuvant Therapy | 2 | 2017 | 125 | 0.070 |
Why?
| Sensitivity and Specificity | 3 | 2016 | 923 | 0.070 |
Why?
| Carbon | 1 | 2005 | 61 | 0.070 |
Why?
| Alkanes | 1 | 2005 | 9 | 0.070 |
Why?
| Spectrometry, Mass, Electrospray Ionization | 1 | 2005 | 67 | 0.070 |
Why?
| Tumor Suppressor Proteins | 1 | 2006 | 141 | 0.070 |
Why?
| Antibodies, Monoclonal, Humanized | 1 | 2007 | 240 | 0.070 |
Why?
| JNK Mitogen-Activated Protein Kinases | 1 | 2005 | 78 | 0.060 |
Why?
| Neoplasm Staging | 2 | 2019 | 806 | 0.060 |
Why?
| Niacinamide | 1 | 2005 | 25 | 0.060 |
Why?
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 1 | 2006 | 150 | 0.060 |
Why?
| Transplantation, Heterologous | 2 | 2021 | 77 | 0.060 |
Why?
| Cell Cycle Proteins | 1 | 2006 | 199 | 0.060 |
Why?
| Neoplasm Recurrence, Local | 1 | 2009 | 644 | 0.060 |
Why?
| Administration, Inhalation | 1 | 2005 | 119 | 0.060 |
Why?
| Rats, Inbred F344 | 1 | 2005 | 209 | 0.060 |
Why?
| Lichen Planus, Oral | 1 | 2004 | 1 | 0.060 |
Why?
| Amines | 1 | 2004 | 46 | 0.060 |
Why?
| Drug Combinations | 2 | 2018 | 128 | 0.060 |
Why?
| Leukoplakia, Oral | 1 | 2004 | 8 | 0.060 |
Why?
| Wind | 1 | 2004 | 5 | 0.060 |
Why?
| Photochemistry | 1 | 2004 | 21 | 0.060 |
Why?
| Hydrocarbons | 1 | 2004 | 9 | 0.060 |
Why?
| Buthionine Sulfoximine | 1 | 2024 | 17 | 0.060 |
Why?
| Cities | 2 | 2017 | 19 | 0.060 |
Why?
| Cations | 1 | 2023 | 15 | 0.060 |
Why?
| Dose-Response Relationship, Drug | 4 | 2009 | 1476 | 0.060 |
Why?
| Monoterpenes | 1 | 2003 | 5 | 0.060 |
Why?
| Photoacoustic Techniques | 2 | 2016 | 86 | 0.060 |
Why?
| Carboplatin | 1 | 2024 | 62 | 0.060 |
Why?
| Binding Sites | 2 | 2021 | 440 | 0.060 |
Why?
| Nanomedicine | 1 | 2023 | 22 | 0.060 |
Why?
| Photosensitizing Agents | 1 | 2023 | 24 | 0.060 |
Why?
| Organic Chemicals | 1 | 2003 | 16 | 0.060 |
Why?
| Sphingomyelin Phosphodiesterase | 1 | 2003 | 10 | 0.060 |
Why?
| Mass Spectrometry | 2 | 2019 | 313 | 0.060 |
Why?
| Statistics, Nonparametric | 1 | 2004 | 232 | 0.060 |
Why?
| Phosphorylation | 3 | 2017 | 614 | 0.060 |
Why?
| Hepatitis B virus | 1 | 2023 | 24 | 0.060 |
Why?
| Kidney Diseases | 1 | 2007 | 293 | 0.060 |
Why?
| Mitogen-Activated Protein Kinase Kinases | 1 | 2003 | 39 | 0.060 |
Why?
| G2 Phase | 1 | 2003 | 15 | 0.060 |
Why?
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2016 | 37 | 0.060 |
Why?
| Quinazolines | 1 | 2003 | 39 | 0.060 |
Why?
| Mammary Neoplasms, Animal | 1 | 2003 | 38 | 0.060 |
Why?
| Anions | 1 | 2022 | 9 | 0.060 |
Why?
| DNA-Binding Proteins | 1 | 2006 | 462 | 0.060 |
Why?
| Aged | 3 | 2021 | 10041 | 0.060 |
Why?
| Prognosis | 2 | 2009 | 2118 | 0.060 |
Why?
| Tumor Suppressor Protein p53 | 1 | 2004 | 250 | 0.060 |
Why?
| Endothelium, Vascular | 1 | 2005 | 288 | 0.060 |
Why?
| Interferons | 1 | 2022 | 44 | 0.050 |
Why?
| Acetone | 1 | 2022 | 6 | 0.050 |
Why?
| Analysis of Variance | 1 | 2004 | 635 | 0.050 |
Why?
| Polyphosphates | 1 | 2022 | 2 | 0.050 |
Why?
| Rifampin | 1 | 2022 | 57 | 0.050 |
Why?
| Inositol | 1 | 2022 | 16 | 0.050 |
Why?
| Heating | 1 | 2022 | 7 | 0.050 |
Why?
| Receptors, Vascular Endothelial Growth Factor | 1 | 2002 | 25 | 0.050 |
Why?
| Pain Measurement | 1 | 2023 | 246 | 0.050 |
Why?
| Propionates | 1 | 2002 | 28 | 0.050 |
Why?
| Ions | 1 | 2022 | 38 | 0.050 |
Why?
| Pain Management | 1 | 2023 | 155 | 0.050 |
Why?
| Ferrets | 1 | 2021 | 6 | 0.050 |
Why?
| Demography | 1 | 2022 | 99 | 0.050 |
Why?
| Hepatocytes | 1 | 2023 | 214 | 0.050 |
Why?
| Income | 1 | 2022 | 102 | 0.050 |
Why?
| Drug Resistance, Neoplasm | 1 | 2024 | 309 | 0.050 |
Why?
| Analgesics, Opioid | 1 | 2007 | 501 | 0.050 |
Why?
| Bays | 1 | 2021 | 1 | 0.050 |
Why?
| Estuaries | 1 | 2021 | 1 | 0.050 |
Why?
| Protein Isoforms | 1 | 2022 | 124 | 0.050 |
Why?
| San Francisco | 1 | 2021 | 11 | 0.050 |
Why?
| Hydrodynamics | 1 | 2021 | 11 | 0.050 |
Why?
| Models, Economic | 1 | 2021 | 19 | 0.050 |
Why?
| Reproducibility of Results | 2 | 2022 | 1304 | 0.050 |
Why?
| Catalytic Domain | 1 | 2021 | 62 | 0.050 |
Why?
| Mice, Inbred NOD | 1 | 2021 | 99 | 0.050 |
Why?
| Cricetinae | 1 | 2021 | 209 | 0.050 |
Why?
| Middle Aged | 3 | 2021 | 13070 | 0.050 |
Why?
| Protein Structure, Tertiary | 2 | 2017 | 289 | 0.050 |
Why?
| Phosphates | 1 | 2021 | 51 | 0.050 |
Why?
| Half-Life | 1 | 2021 | 92 | 0.050 |
Why?
| Mutagenesis, Insertional | 1 | 2021 | 28 | 0.050 |
Why?
| Administration, Intravenous | 1 | 2021 | 75 | 0.050 |
Why?
| Micronucleus Tests | 1 | 2020 | 9 | 0.050 |
Why?
| Cell Division | 1 | 2002 | 330 | 0.050 |
Why?
| Molecular Docking Simulation | 1 | 2021 | 83 | 0.050 |
Why?
| Cell Line, Transformed | 1 | 2021 | 88 | 0.050 |
Why?
| Bayes Theorem | 1 | 2021 | 123 | 0.050 |
Why?
| ROC Curve | 1 | 2021 | 259 | 0.050 |
Why?
| Catecholamines | 1 | 2020 | 48 | 0.050 |
Why?
| Adult | 3 | 2021 | 14182 | 0.050 |
Why?
| Limbic Encephalitis | 1 | 2020 | 2 | 0.050 |
Why?
| Software | 2 | 2016 | 296 | 0.050 |
Why?
| Elastin | 1 | 2020 | 22 | 0.050 |
Why?
| Monte Carlo Method | 1 | 2020 | 99 | 0.050 |
Why?
| Primary Cell Culture | 1 | 2020 | 65 | 0.050 |
Why?
| ADAM Proteins | 1 | 2020 | 24 | 0.050 |
Why?
| Antiviral Agents | 1 | 2021 | 188 | 0.050 |
Why?
| Epitopes | 1 | 2020 | 89 | 0.050 |
Why?
| Facility Design and Construction | 1 | 2019 | 3 | 0.050 |
Why?
| Autoantigens | 1 | 2020 | 64 | 0.050 |
Why?
| Prospective Studies | 2 | 2017 | 2604 | 0.050 |
Why?
| Cytoprotection | 1 | 2019 | 48 | 0.050 |
Why?
| HeLa Cells | 1 | 2020 | 291 | 0.050 |
Why?
| Endothelium | 1 | 2019 | 45 | 0.040 |
Why?
| Intercellular Adhesion Molecule-1 | 1 | 2019 | 75 | 0.040 |
Why?
| Glioma | 1 | 2020 | 78 | 0.040 |
Why?
| Energy Intake | 1 | 2020 | 196 | 0.040 |
Why?
| Interdisciplinary Communication | 1 | 2019 | 64 | 0.040 |
Why?
| Stress, Physiological | 1 | 2020 | 194 | 0.040 |
Why?
| Pancreatic Neoplasms | 1 | 2002 | 234 | 0.040 |
Why?
| Diffusion Chambers, Culture | 1 | 2018 | 8 | 0.040 |
Why?
| Culture Media, Serum-Free | 1 | 2018 | 20 | 0.040 |
Why?
| Swine | 2 | 2011 | 431 | 0.040 |
Why?
| Culture Media, Conditioned | 1 | 2018 | 52 | 0.040 |
Why?
| Laminin | 1 | 2018 | 29 | 0.040 |
Why?
| Hep G2 Cells | 1 | 2018 | 46 | 0.040 |
Why?
| Specimen Handling | 1 | 2018 | 62 | 0.040 |
Why?
| Flavin-Adenine Dinucleotide | 1 | 2018 | 5 | 0.040 |
Why?
| Dextrans | 1 | 2018 | 20 | 0.040 |
Why?
| Calcium-Binding Proteins | 1 | 2018 | 61 | 0.040 |
Why?
| NAD | 1 | 2018 | 46 | 0.040 |
Why?
| Hydrophobic and Hydrophilic Interactions | 1 | 2018 | 42 | 0.040 |
Why?
| Program Development | 1 | 2019 | 199 | 0.040 |
Why?
| Surface Properties | 1 | 2018 | 79 | 0.040 |
Why?
| Skin Neoplasms | 1 | 2004 | 532 | 0.040 |
Why?
| Imides | 1 | 2018 | 1 | 0.040 |
Why?
| Proteoglycans | 1 | 2018 | 96 | 0.040 |
Why?
| Follow-Up Studies | 1 | 2004 | 2387 | 0.040 |
Why?
| Feces | 1 | 2018 | 135 | 0.040 |
Why?
| Mid-Atlantic Region | 1 | 2017 | 7 | 0.040 |
Why?
| Hippocampus | 1 | 2020 | 242 | 0.040 |
Why?
| New England | 1 | 2017 | 10 | 0.040 |
Why?
| Human Activities | 1 | 2017 | 6 | 0.040 |
Why?
| Macaca fascicularis | 1 | 2017 | 9 | 0.040 |
Why?
| Body Weight | 1 | 2020 | 578 | 0.040 |
Why?
| Ubiquitin | 1 | 2018 | 51 | 0.040 |
Why?
| Caco-2 Cells | 1 | 2017 | 50 | 0.040 |
Why?
| Carbohydrates | 1 | 2018 | 64 | 0.040 |
Why?
| Repetitive Sequences, Nucleic Acid | 1 | 2018 | 92 | 0.040 |
Why?
| Neoplasm Metastasis | 1 | 2018 | 252 | 0.040 |
Why?
| Autophagy | 1 | 2019 | 202 | 0.040 |
Why?
| Guidelines as Topic | 1 | 2018 | 125 | 0.040 |
Why?
| Cooperative Behavior | 1 | 2019 | 254 | 0.040 |
Why?
| Adaptor Proteins, Signal Transducing | 1 | 2018 | 208 | 0.040 |
Why?
| Phagocytosis | 1 | 2017 | 51 | 0.040 |
Why?
| Nanotubes | 1 | 2017 | 38 | 0.040 |
Why?
| Cell Movement | 1 | 2018 | 271 | 0.040 |
Why?
| Drug Interactions | 1 | 2017 | 206 | 0.040 |
Why?
| Collagen | 1 | 2018 | 223 | 0.040 |
Why?
| Pyrazoles | 1 | 2018 | 110 | 0.040 |
Why?
| Clinical Trials, Phase II as Topic | 1 | 2017 | 51 | 0.040 |
Why?
| Cricetulus | 1 | 2017 | 102 | 0.040 |
Why?
| Inflammation | 1 | 2021 | 674 | 0.040 |
Why?
| CHO Cells | 1 | 2017 | 123 | 0.040 |
Why?
| Gene Frequency | 1 | 2017 | 120 | 0.040 |
Why?
| Chromatography, Liquid | 1 | 2017 | 243 | 0.040 |
Why?
| Cohort Studies | 1 | 2021 | 1543 | 0.040 |
Why?
| Proto-Oncogene Proteins c-sis | 1 | 2016 | 9 | 0.040 |
Why?
| Drug Therapy, Combination | 1 | 2018 | 426 | 0.040 |
Why?
| DNA Repair | 1 | 2018 | 202 | 0.040 |
Why?
| Drug Screening Assays, Antitumor | 2 | 2008 | 142 | 0.040 |
Why?
| Fires | 1 | 2016 | 19 | 0.040 |
Why?
| Taxoids | 1 | 2016 | 45 | 0.040 |
Why?
| Interleukin-1alpha | 1 | 2016 | 13 | 0.040 |
Why?
| Platelet-Derived Growth Factor | 1 | 2016 | 23 | 0.040 |
Why?
| Receptors, Progesterone | 1 | 2016 | 57 | 0.040 |
Why?
| Wetlands | 1 | 2015 | 2 | 0.030 |
Why?
| Hindlimb Suspension | 1 | 2016 | 45 | 0.030 |
Why?
| Particle Accelerators | 1 | 2016 | 50 | 0.030 |
Why?
| Diet | 1 | 2020 | 597 | 0.030 |
Why?
| Dicumarol | 2 | 2005 | 3 | 0.030 |
Why?
| Regression Analysis | 1 | 2017 | 445 | 0.030 |
Why?
| Receptors, Estrogen | 1 | 2016 | 131 | 0.030 |
Why?
| Ecology | 1 | 2015 | 15 | 0.030 |
Why?
| Cyclophosphamide | 1 | 2016 | 172 | 0.030 |
Why?
| Carbonic Anhydrases | 1 | 2015 | 5 | 0.030 |
Why?
| Matrix Metalloproteinase 2 | 1 | 2015 | 64 | 0.030 |
Why?
| Energy Metabolism | 1 | 2018 | 311 | 0.030 |
Why?
| Molecular Structure | 2 | 2008 | 319 | 0.030 |
Why?
| Sulfur Dioxide | 1 | 2015 | 3 | 0.030 |
Why?
| Muscular Atrophy | 1 | 2016 | 73 | 0.030 |
Why?
| Genotype | 1 | 2017 | 599 | 0.030 |
Why?
| Public Policy | 1 | 2015 | 40 | 0.030 |
Why?
| Models, Animal | 1 | 2016 | 255 | 0.030 |
Why?
| Norepinephrine | 1 | 2015 | 119 | 0.030 |
Why?
| Epinephrine | 1 | 2015 | 97 | 0.030 |
Why?
| Mice, Knockout | 1 | 2017 | 926 | 0.030 |
Why?
| Risk | 1 | 2015 | 343 | 0.030 |
Why?
| Doxorubicin | 1 | 2016 | 259 | 0.030 |
Why?
| Weight Gain | 1 | 2016 | 243 | 0.030 |
Why?
| Feeding Behavior | 1 | 2016 | 199 | 0.030 |
Why?
| Inhibitory Concentration 50 | 2 | 2004 | 80 | 0.030 |
Why?
| Culture Media | 2 | 2004 | 100 | 0.030 |
Why?
| Aged, 80 and over | 1 | 2021 | 3429 | 0.030 |
Why?
| Models, Immunological | 1 | 2013 | 10 | 0.030 |
Why?
| Glucocorticoids | 1 | 2015 | 234 | 0.030 |
Why?
| Anti-Bacterial Agents | 1 | 2019 | 820 | 0.030 |
Why?
| Nuclear Magnetic Resonance, Biomolecular | 1 | 2013 | 34 | 0.030 |
Why?
| Bone Resorption | 1 | 2016 | 326 | 0.030 |
Why?
| Protein Structure, Secondary | 1 | 2013 | 99 | 0.030 |
Why?
| DNA Breaks, Double-Stranded | 1 | 2013 | 78 | 0.030 |
Why?
| Chronic Disease | 1 | 2015 | 612 | 0.030 |
Why?
| Light | 1 | 2013 | 82 | 0.030 |
Why?
| Decision Making | 1 | 2015 | 290 | 0.030 |
Why?
| Rats, Sprague-Dawley | 1 | 2016 | 1663 | 0.030 |
Why?
| Computer-Aided Design | 1 | 2011 | 21 | 0.030 |
Why?
| Adjuvants, Pharmaceutic | 1 | 2011 | 3 | 0.030 |
Why?
| Equipment Failure Analysis | 1 | 2011 | 49 | 0.030 |
Why?
| Mutation | 1 | 2018 | 1501 | 0.020 |
Why?
| Phantoms, Imaging | 1 | 2011 | 126 | 0.020 |
Why?
| Volatilization | 1 | 2010 | 5 | 0.020 |
Why?
| Leukocyte Count | 1 | 2010 | 77 | 0.020 |
Why?
| Equipment Design | 1 | 2011 | 318 | 0.020 |
Why?
| Solvents | 1 | 2010 | 35 | 0.020 |
Why?
| Glucagon-Like Peptide 1 | 1 | 2009 | 31 | 0.020 |
Why?
| Air | 1 | 2009 | 26 | 0.020 |
Why?
| Geography | 1 | 2010 | 81 | 0.020 |
Why?
| Amides | 1 | 2009 | 43 | 0.020 |
Why?
| Dogs | 1 | 2009 | 217 | 0.020 |
Why?
| Muscle, Skeletal | 1 | 2016 | 847 | 0.020 |
Why?
| Proliferating Cell Nuclear Antigen | 1 | 2009 | 82 | 0.020 |
Why?
| Retrospective Studies | 1 | 2022 | 6432 | 0.020 |
Why?
| Receptor, IGF Type 1 | 1 | 2009 | 19 | 0.020 |
Why?
| Insulin-Like Growth Factor Binding Proteins | 1 | 2009 | 27 | 0.020 |
Why?
| Thermal Conductivity | 1 | 2009 | 7 | 0.020 |
Why?
| Mammary Glands, Animal | 1 | 2009 | 69 | 0.020 |
Why?
| Binding, Competitive | 1 | 2009 | 113 | 0.020 |
Why?
| Pharmacokinetics | 1 | 2008 | 18 | 0.020 |
Why?
| Chromatography, High Pressure Liquid | 1 | 2010 | 377 | 0.020 |
Why?
| Guinea Pigs | 1 | 2008 | 89 | 0.020 |
Why?
| Child | 1 | 2021 | 7337 | 0.020 |
Why?
| Isatin | 1 | 2008 | 1 | 0.020 |
Why?
| Models, Statistical | 1 | 2010 | 259 | 0.020 |
Why?
| Drug Design | 1 | 2009 | 133 | 0.020 |
Why?
| Auditory Threshold | 1 | 2008 | 47 | 0.020 |
Why?
| Probability | 1 | 2008 | 176 | 0.020 |
Why?
| Glycosylphosphatidylinositols | 1 | 2007 | 33 | 0.020 |
Why?
| Bone Marrow | 1 | 2010 | 411 | 0.020 |
Why?
| Weight Loss | 1 | 2010 | 271 | 0.020 |
Why?
| Crystallography, X-Ray | 1 | 2008 | 178 | 0.020 |
Why?
| Recurrence | 1 | 2009 | 690 | 0.020 |
Why?
| Rubidium | 1 | 2006 | 6 | 0.020 |
Why?
| Isoelectric Point | 1 | 2005 | 5 | 0.020 |
Why?
| Isoelectric Focusing | 1 | 2005 | 13 | 0.020 |
Why?
| Peptide Mapping | 1 | 2005 | 22 | 0.020 |
Why?
| Caffeine | 1 | 2006 | 77 | 0.020 |
Why?
| Air Movements | 1 | 2005 | 1 | 0.020 |
Why?
| Severity of Illness Index | 1 | 2009 | 1084 | 0.020 |
Why?
| Quality Control | 1 | 2005 | 101 | 0.020 |
Why?
| Tumor Stem Cell Assay | 1 | 2004 | 21 | 0.020 |
Why?
| Cell Cycle | 1 | 2006 | 275 | 0.020 |
Why?
| Liver | 1 | 2011 | 1225 | 0.020 |
Why?
| Tennessee | 1 | 2003 | 43 | 0.010 |
Why?
| Diabetes Mellitus, Type 2 | 1 | 2009 | 481 | 0.010 |
Why?
| HL-60 Cells | 1 | 2003 | 24 | 0.010 |
Why?
| Solubility | 1 | 2003 | 75 | 0.010 |
Why?
| Bacterial Proteins | 1 | 2007 | 454 | 0.010 |
Why?
| Cyclin B | 1 | 2003 | 6 | 0.010 |
Why?
| Cyclin B1 | 1 | 2003 | 8 | 0.010 |
Why?
| CDC2 Protein Kinase | 1 | 2003 | 23 | 0.010 |
Why?
| Water | 1 | 2003 | 102 | 0.010 |
Why?
| Heat-Shock Proteins | 1 | 2003 | 87 | 0.010 |
Why?
| Magnetic Resonance Imaging | 1 | 2004 | 1604 | 0.010 |
Why?
|
|
Griffin's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Derived automatically based on a person's publications. Keywords from attributed publications are matched to keywords from the MeSH. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|